Daewoong Pharmaceuticals Co., Ltd pursues meaningful work by collaborating with great people, working with autonomy, and choosing opportunities that create shared value for the company, customers, and society. Above all, we are committed to driving real change and innovation through what we do. Establish in 1945, Daewoong Pharmaceuticals is a leading healthcare company in Korea that has achieved consecutive successes in new drug development through constant challenge and innovation. Today, we continue to expand a diverse pipeline and next-generation platform technologies, aiming to develop first-in-class and best-in-class innovative medicines for patients worldwide. Our commitment to global standards is proven by GMP certifications from major regulatory authorities such as the U.S. FDA and EMA, along with ISO certifications that demonstrate our excellence in quality, environmental management, and occupational health and safety systems. At Daewoong, we believe that the growth of our employees fuels the growth of the company. We foster a forward-looking corporate culture by promoting smart work practices, career development, and global talent training programs. Beyond Korea, we strive to become a global healthcare leader by creating new value for healthier lives and better quality of life worldwide.
我们正在追踪 Daewoong Pharmaceutical 的市场扩张
最近 90 天内有 92 个信号。
Daewoong Pharmaceutical 的国际扩张与竞争对手的对比情况
Daewoong Pharmaceutical你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Daewoong Pharmaceutical你 | 0 | 0 | — | 0 | 0 |
Senior Partnership & Leasing - Bali
查看职位Kuta, Bali, Indonesia · 5个月前
Chief Engineer - Bali
查看职位Kuta, Bali, Indonesia · 5个月前
Cafe Team
查看职位Kuta, Bali, Indonesia · 6个月前
#News 📢 대웅제약 presented integrated model-based research findings on its SGLT-2 inhibitor #Enavogliflozin, at the 2026 PAGE (PAGE - Population Approach Group Europe) conference, a leading European forum in quantitative pharmacology.This study quantitatively elucidated the causal relationship between increased urinary glucose excretion following drug administration and the reduction in glycated hemoglobin (HbA1c), and scientifically demonstrated that the absence of significant pharmacokinetic diff ...
已结束Not all long-acting depot platforms are created equal. The key lies in how efficiently a drug can be delivered — in a smaller volume.In Episode 2 of the "Maximizing Therapeutic Potential with CURE®" series, we explore how CURE® achieves industry-leading drug loading to deliver a once-monthly therapeutic dose with up to 4–5× less depot mass than competing platforms.#Daewoong #GLP1 #CURE #platform #obesity #diseases #longactinginjectables ...
已结束Small differences in wording can easily lead to misunderstandings in pharmaceutical communication.✍️👩💻Ji Young Yoon from 대웅제약’s Medical Team took on the challenge of bringing clarity to the confusion surrounding UDCA-related scientific messages, which had been spreading across multiple channels during the pandemic. By restructuring the messaging system, she helped ensure that accurate, evidence-based information could be delivered consistently.Curious about her journey? Watch the full video no ...
进行中大熊制药今年数字医疗销售目标3000亿韩元，推出整合人工智能医疗平台，计划全国远程健康监测。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Daewoong Pharmaceutical 的业务、市场和增长信号的快速解答。
